AZN241122P58000
- 0.09
- 0.000.00%
AstraZeneca Newsroom
CHMP Endorses AstraZeneca's Tagrisso for Expanded Use in NSCLC
Leerink Partners Maintains AstraZeneca(AZN.US) With Buy Rating, Announces Target Price $87
TD Cowen Maintains AstraZeneca(AZN.US) With Buy Rating
High dividend lovers cannot miss it! blackrock's new etf brings together global high dividend stocks.
BlackRock (BLK.US) announced on Monday that the institution has launched its first actively managed international high-dividend etf listed on the usa stock market—the BlackRock International Dividend ETF.
GRAIL Says First Person Tested With Blood-Based Assay in Lung Cancer Trial
GRAIL Announces The First Patient Has Been Tested For Eligibility With Its Non-Small Cell Lung Cancer CtDNA Assay In The TROPION-Lung12 Phase 3 Study, Sponsored By AstraZeneca In Collaboration With Daiichi Sankyo
AstraZeneca Picks First Treg Cell Therapy From Quell Therapeutics Partnership
Astrazeneca (AZN) Is a Top-Ranked Growth Stock: Should You Buy?
Express News | Lunit Announces Collaboration With AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for Nsclc
Lunit Announces Collaboration With AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC
Is AstraZeneca PLC (AZN) the Best Immunotherapy Stock to Buy Now?
TD Cowen Remains a Buy on AstraZeneca (AZN)
AstraZeneca's Tagrisso Recommended for Inoperable Non-Small Cell Lung Cancer in Europe
Express News | AstraZeneca : Leerink Partners Raises Target Price to $87 From $86
Pharmaceutical Sector Outlook for 2025 Looks Rocky -- Market Talk
EU Panel Recommends AstraZeneca's Lung Cancer Drug Tagrisso for Approval
AstraZeneca's Tagrisso Gains EU Approval Nod
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Trending Stocks This Week as Wall Street Sells off Amid Fed Remarks
US Manufacturing Index Rises To 43, Highest Since 2020